Φορτώνει......
Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma
Multiple myeloma (MM) is a relapsed and refractory disease, one that highlights the need for developing new molecular therapies for overcoming of drug resistance. Addition of panobinostat, a histone deacetylase (HDAC) inhibitor, to bortezomib and dexamethasone improved progression-free survival (PFS...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | JCI Insight |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
American Society for Clinical Investigation
2016
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5033869/ https://ncbi.nlm.nih.gov/pubmed/27699258 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.85061 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|